Quetmolimab
Based on 1 Customer Validation
Quetmolimab (E6011) is a humanized anti-Fractalkine (CX3CL1) monoclonal antibody. Quetmolimab binds to membrane-bound and soluble Fractalkine, neutralizes Fractalkine-induced migration of CX3CR1-expressing cells, mediates target-bound complex elimination from serum. Quetmolimab suppresses free soluble Fractalkine levels in cynomolgus monkeys, with target engagement linked to increased serum total Fractalkine concentration. Quetmolimab can be used for the research of Crohn’s disease, rheumatoid arthritis, and primary biliary cholangitis.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.9%
- CAS No.: 2084037-83-0
- Masse moléculaire:144.72 kDa
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Pureté et documentation
- Références
-
Help & FAQs
Activité biologique
Human IgG2 kappa
Human
CX3CL1/Fractalkine
Quetmolimab (E6011) inhibits fractalkine-induced migration of human CX3CR1-transfected B300.19 mouse B-lymphocyte precursors, with a minimum active concentration of 3.2 ng/mL for 10% maximal suppression of free soluble FKN from baseline[1].
Quetmolimab binds to soluble human fractalkine with a mean equilibrium dissociation constant of 0.27 μg/mL[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Cynomolgus monkeys (median body weight 3.44 kg)[1]
-
Dosage:0.05-100 mg/kg
-
Administration:i.v.; single infusion
-
Result:Exhibited a triphasic elimination profile, with dose-dependent increases in exposure where area under the concentration-time curve (AUC) increased more than proportionally to dose.
Increased serum total FKN concentration, confirming target engagement.
Reached a maximum effect (EMAX) of 0.974, indicating near-complete suppression of free soluble FKN elimination at sufficient concentrations.
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Human IgG2 kappa
ELISA, FACS, Functional assay
-
Immobilized Fractalkine/CX3CL1 Protein, Human (HY-P7180) can bind Quetmolimab. The EC50 for this effect is 3.65 ng/mL.
Chemical Information
-
CAS No. 2084037-83-0
-
Appearance Liquid
-
Masse moléculaire 144.72 kDa
-
Color Colorless to light yellow
-
SMILES
[Quetmolimab]
-
Synonyms
E6011
-
Livraison
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
-
Fiche technique (260 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Inhibitory Antibodies User Guide (603 KB)
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Quetmolimab Related Classifications
HY-P99404 Related Classifications
Powered by Bioz